相关实验视频

Updated: Jul 26, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

用杜尔瓦卢马布成功治疗:一个病例报告和综述

Ana Peláez Bejarano¹, Olalla Montero Pérez¹

¹Hospital Pharmacy, Unidad de Gestión Clínica Farmacia, Hospital Juan Ramón Jiménez, Huelva, Spain.

Journal of cancer research and therapeutics

|June 14, 2023

概括

杜尔瓦卢马布为不可切除的IIIA期非小细胞肺癌 (NSCLC) 提供了一个新的治疗选择. 这项案例研究表明,在杜尔瓦卢马布治疗后20个多月的时间里,成功控制了疾病.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.

背景情况:

第三阶段非小细胞肺癌 (NSCLC) 治疗通常涉及多模式方法.
基于的双剂与并发化学放射治疗 (CRT) 是大多数第三阶段NSCLC患者的标准一线治疗.
尽管转移性NSCLC的进展,但第三阶段NSCLC的全身治疗选择仍然有限.

研究的目的:

报告一例使用杜尔瓦卢马布成功治疗不可切除的IIIA期非小细胞肺癌 (NSCLC) 的病例.
突出免疫检查点抑制剂在管理局部先进NSCLC方面的潜力.

主要方法:

一名患有无法切除的IIIA期NSCLC的患者接受了杜尔瓦卢马布治疗.
患者接受了1年不间断的杜尔瓦卢马布治疗.

主要成果:

患者成功控制了疾病.
在开始杜尔瓦卢马布治疗后,疾病控制持续了超过20个月.

结论:

杜尔瓦卢马布可以成为无法切除的IIIA期NSCLC患者的有效治疗选择.
免疫检查点抑制显示了改善局部发达NSCLC的结果的希望.

关键词:

反编程细胞死亡配体1 整合的整合是指整合.达尔瓦卢马布 (Durvalumab) 是一种耐用药.免疫疗法免疫疗法其他非小细胞肺癌.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...